Clinical trials: Advanced and/or Metastatic Solid Tumours
Unresectable Locally Advanced or Metastatic Cancer
First-in-Human Study of TAK-280 in Participants With Solid Tumors
The main aim of this study is to find out the safety, tolerability, and effect of TAK- 280 in participants with unresectable, locally advanced or metastatic cancer who have experienced treatment failure or are intolerant to…
- Trial name
- NCT05220098
- Testing
- TAK-280
- Where
- 23 sites in United States, Australia and 2 more
- Volunteers
- 69 people
- Sponsor
- Takeda
Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
This is a first-in-human, open-label, multicenter phase 1 study to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of OP-3136, a lysine acetyltransferases 6A and 6B (KAT6A/B)…
- Conditions
- Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Breast Cancer
- Trial name
- NCT06784193
- Testing
- OP-3136, Fulvestrant, Palazestrant
- Where
- 25 sites in United States, Australia and 4 more
- Volunteers
- 180 people
- Sponsor
- Olema Pharmaceuticals, Inc.
Advanced or Metastatic Solid Tumors
A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001)
The purpose of this study is to assess the efficacy and safety and establish a preliminary recommended Phase 2 dose (RP2D) of MK-6598 administered as monotherapy and in combination with pembrolizumab (MK-3475) in adult…
- Trial name
- NCT05594043
- Testing
- MK-6598, Pembrolizumab
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 39 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumor, Metastatic Cancer
Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer
This is a multicenter, open label, Phase 1 dose escalation study of TJ004309 in combination with standard dose atezolizumab in patients with advanced or metastatic cancer in patients who are refractory to or intolerant to all…
- Trial name
- NCT03835949
- Testing
- TJ004309, Atezolizumab
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Metastatic Malignant Neoplasm, Solid Neoplasm
Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery
This pilot phase I trial studies how well ilorasertib works in treating patients with cyclin-dependent kinase inhibitor 2A (CDKN2A)-deficient solid cancers that have spread to other places in the body and usually cannot be cured…
- Conditions
- Metastatic Malignant Neoplasm, Solid Neoplasm, Unresectable Malignant Neoplasm
- Trial name
- NCT02540876
- Testing
- Ilorasertib, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Chicago
Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC)
XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
This is a global, multi-center, open-label, Phase I/II first-in-human study of XNW27011 monotherapy as an investigational product (IP) in patients with locally advanced and/or metastatic solid tumors who have failed or are…
- Conditions
- Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC), Ovarian Cancer, Colorectal Cancer Metastatic
- Trial name
- NCT06792435
- Testing
- XNW27011
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Neoplasms
A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
This multi-center, open-label study will evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of vanucizumab as a single agent or in combination with atezolizumab in participants with locally advanced…
- Trial name
- NCT01688206
- Testing
- Atezolizumab [TECENTRIQ], Vanucizumab
- Where
- 14 sites in Belgium, France and 1 more
- Volunteers
- 132 people
- Sponsor
- Hoffmann-La Roche
Solid Tumor
A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors
This is a phase I trial with BYON4228, a humanized monoclonal antibody (mAb) directed against signal regulatory protein (SIRP)α in solid tumors, alone and in combination with pembrolizumab.
- Trial name
- NCT06932952
- Testing
- BYON4228 + Pembrolizumab
- Where
- 6 sites in Belgium, Spain and 1 more
- Volunteers
- 7 people
- Sponsor
- Byondis B.V.
Malignant Solid Tumor
A Safety and Pharmacokinetic Phase I/Ib Study of AMC303 in Patients With Solid Tumours
This is a two part Phase I/Ib, open-label, non-randomized and multi-center, dose escalation study with a 3+3 design (Part 1) and an expansion cohort at the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) (Part 2).
- Trial name
- NCT03009214
- Testing
- AMC303
- Where
- 7 sites in Belgium, Spain
- Volunteers
- 55 people
- Sponsor
- amcure GmbH
Tumors
to evaluate188Re-BMEDA-liposome in Patient With Primary Solid Tumor in Advanced or Metastatic Stage
This is a study to determine the maximum tolerance dose (MTD) and to evaluate the safety of 188Re-BMEDA-liposome in patient with primary solid tumor in advanced or metastatic stage.
- Trial name
- NCT02271516
- Testing
- 188Re-BMEDA-liposome
- Where
- Taiwan
- Volunteers
- 3 people
- Sponsor
- National Atomic Research Institute, Taiwan
Locally Advanced or Metastatic Malignant Solid Tumors
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Specific proteins found in tumors help the tumors spread and grow. People with solid tumors often have a protein called TROP2 in their tumor.
- Trial name
- NCT07287995
- Testing
- ASP2998, Pembrolizumab, Enfortumab Vedotin
- Where
- 9 sites in United States, Japan
- Volunteers
- 428 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Advanced or Metastatic Solid Tumors
A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients
This is a phase I, open-label, multi-center, dose escalation and expansion study in advanced or metastatic solid tumor patients.
- Trial name
- NCT07260305
- Testing
- KGX101 injection, Envafolimab
- Where
- 3 sites in China
- Volunteers
- 57 people
- Sponsor
- Kangabio AUSTRALIA LTD PTY
Mesothelioma, Glioblastoma
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
- Conditions
- Mesothelioma, Glioblastoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT04913337
- Testing
- NGM707, NGM707 plus pembrolizumab (KEYTRUDA®)
- Where
- 27 sites in United States, South Korea and 1 more
- Volunteers
- 179 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Neoplasm Metastasis
Study of DS-8201a for Participants With Advanced Solid Malignant Tumors
HER2-positive cancer is a cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2). HER2 promotes the growth of certain cancer cells.
- Trial name
- NCT03383692
- Testing
- DS-8201a, Ritonavir, Itraconazole
- Where
- 10 sites in Japan, South Korea and 1 more
- Volunteers
- 40 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Advanced or Metastatic Solid Tumors
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and anti-tumor activity of DAY301, a PTK7-directed antibody-drug conjugate (ADC) in participants with advanced or metastatic solid…
- Trial name
- NCT06752681
- Testing
- DAY301
- Where
- 11 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- Day One Biopharmaceuticals, Inc.
Metastatic or Unresectable Solid Tumor Malignancy
A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors
The investigators propose this Phase I trial of the combination of AUY922 and capecitabine to determine the maximum tolerated dose (MTD) in patients with advanced solid tumors.
- Trial name
- NCT01226732
- Testing
- Capecitabine, Hsp90 Inhibitor AUY 922
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- SCRI Development Innovations, LLC
Solid Tumor
Phase Ⅰ/Ⅱ Study of the HS-10365 in Patients With Advanced Solid Tumors
HS-10365 is a small molecular, oral potent, selective RET inhibitor. The purpose of this study is to investigate the safety/tolerability、the pharmacokinetic profile and efficacy of HS-10365 in Chinese advanced solid tumor…
- Trial name
- NCT05207787
- Testing
- HS-10365
- Where
- China
- Volunteers
- 306 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
This phase Ib trial is to find out the best dose, possible benefits and/or side effects of talazoparib when given in combination with palbociclib, axitinib, or crizotinib in treating patients with solid tumors that has spread to…
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
- Trial name
- NCT04693468
- Testing
- Axitinib, Crizotinib, Palbociclib Isethionate
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- M.D. Anderson Cancer Center
Locally Advanced or Metastatic Solid Tumors, Genes, BRCA 1
Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors
Avelumab in combination with talazoparib will be investigated in patients with locally advanced or metastatic solid tumors with a BRCA or ATM defect.
- Trial name
- NCT03565991
- Testing
- Avelumab, Talazoparib
- Where
- 100 sites in United States, Belgium and 7 more
- Volunteers
- 202 people
- Sponsor
- Pfizer
Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors
This phase Ib/II trial studies the side effects and best dose of trametinib and navitoclax and how well they work in treating patients with solid tumors that have spread to other places in the body (advanced or metastatic).
- Conditions
- Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
- Trial name
- NCT02079740
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 2 sites in United States
- Volunteers
- 96 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.